4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow hydromethylthionine: new trials by email Literature Review of hydromethylthionine trials Research Report on hydromethylthionine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment TRx0237 16 mg/day, Control, TRx0237 8 mg/day - Alzheimer Disease | Phase 3 | Completed | TauRx Therapeutics Ltd | 598 | 2017-12-01 | 2025-09-04 |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) TRx0237, Placebo - Behavioral Variant Frontotemporal Dementia (bvFTD) | Phase 3 | Completed | TauRx Therapeutics Ltd | 220 | 2013-05-01 | 2018-03-14 |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo - Alzheimer's Disease | Phase 3 | Completed | TauRx Therapeutics Ltd | 891 | 2013-01-01 | 2018-03-14 |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease TRx0237 200 mg/day, Placebo - Alzheimer's Disease | Phase 3 | Completed | TauRx Therapeutics Ltd | 800 | 2012-10-01 | 2018-03-14 |
Alzheimer Disease (3) · Brain Diseases (2) · Dementia (2) · Neurodegenerative Diseases (2) · Frontotemporal Dementia (1)
Canada (4) · Italy (4) · Spain (4) · United Kingdom (4) · United States (4) · Australia (3) · Croatia (3) · Germany (3) · Poland (3) · Belgium (2) · France (2) · Netherlands (2) · Romania (2) · Singapore (2) · Bulgaria (1)